Jinyang Wang

2 papers in the library · 6 citations · publishing 2023-2025

Papers

Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.

Cell Biology and Toxicology January 29, 2025 Xiaoming Ji, Zhimin Huang, Chenming Zhou et al. 6 citations

Esketamine, a new antidepressant, reduces depressive-like behavior in mice with neuropathic pain by boosting levels of the m6A methyltransferase METTL3 and the AMPA receptor GluA1 subunit. Esketamine activates METTL3, which binds to GluA1 mRNA and promotes m6A modification, enhancing GluA1 expression at synapses. This mechanism offers new insights into esketamine's potential applications and therapeutic avenues for neuropathic pain and depressive behavior.

DOI: 10.1007/s10565-024-09975-1 Full text Esketamine Depressive behavior M6a methyltransferase mettl3 Neuropathic pain +5

The effects of mindfulness-based interventions on anxiety, depression, stress, and mindfulness in menopausal women: A systematic review and meta-analysis

Frontiers in Public Health January 9, 2023 Hongyang Liu, Kexin Cai, Jinyang Wang et al.

A meta-analysis of 13 studies involving 1,138 menopausal women found that mindfulness-based interventions (MBIs) significantly reduced stress (standardized mean difference −0.84), but showed no statistically significant effects on anxiety, depression, or mindfulness scores. The authors conclude that MBIs may reduce stress in this population, while their impact on other outcomes requires further validation.

DOI: 10.3389/fpubh.2022.1045642